Federico Esteso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Federico Esteso has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Andres Rodriguez
Department of Gastrointestinal Tumors, Alexander Fleming Institute, Buenos Aires, Argentina.; Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Argentina., Argentina
1 shared publication - Berenice Freile
Department of Gastrointestinal Tumors, Alexander Fleming Institute, Buenos Aires, Argentina, Equipo Multidisciplinario de Oncología Gastrointestinal (EMOGI), Asociación Argentina de Oncología Clínica, Argentina., Argentina
1 shared publication - Greta Catani
Gastrointestinal Tumors Department, Alexander Fleming Institute, Buenos Aires, Argentina
1 shared publication - Juan Manuel O'Connor
Instituto Alexander Fleming, Buenos Aires, Argentina
1 shared publication - Luisina Bruno
Instituto Alexander Fleming, Argentina
1 shared publication - Marcos Bortz
Department of Oncology, Alexander Fleming Institute, Buenos Aires 1426, Argentina
1 shared publication
Latest Publications
- Open Access
- 15 August 2024
- Published by MDPI AG in Preprints.org
Targeted Therapies in Neoadjuvant Treatment for Gastroesophageal Cancer
Gastroesophageal cancers, are among the most prevalent cancers globally and represent the third leading cause of cancer-related mortality worldwide. Surgical resection remains the primary curative approach for localized and locally advanced stages, but its effectiveness is limited for locally advanced diseases, evidenced by a low 5-year survival rate of around 25%. High relapse rates post-surgery, particularly in western populations, necessitate the use of neoadjuvant, adjuvant, or perioperative strategies involving chemotherapy and radiation to improve surgical outcomes. Neoadjuvant chemoradiation therapy has demonstrated a significant improvement in overall survival. Recent advances have identified several target genes and pathways involved in the pathogenesis and progression of these cancers, leading to the development of targeted drugs, including immunotherapy, anti-HER-2 antibodies, and anti-VEGFR antibodies. These targeted therapies are emerging as promising interventions for better patient outcomes and personalized treatment approaches and therefore could eventually evolve into a novel therapeutic regimen for gastroesophageal cancer.
- 15 August 2024
- Published by MDPI AG in Preprints.org
Open AccessTargeted Therapies in Neoadjuvant Treatment for Gastroesophageal Cancer
Gastroesophageal cancers, are among the most prevalent cancers globally and represent the third leading cause of cancer-related mortality worldwide. Surgical resection remains the primary curative approach for localized and locally advanced stages, but its effectiveness is limited for locally advanced diseases, evidenced by a low 5-year survival rate of around 25%. High relapse rates post-surgery, particularly in western populations, necessitate the use of neoadjuvant, adjuvant, or perioperative strategies involving chemotherapy and radiation to improve surgical outcomes. Neoadjuvant chemoradiation therapy has demonstrated a significant improvement in overall survival. Recent advances have identified several target genes and pathways involved in the pathogenesis and progression of these cancers, leading to the development of targeted drugs, including immunotherapy, anti-HER-2 antibodies, and anti-VEGFR antibodies. These targeted therapies are emerging as promising interventions for better patient outcomes and personalized treatment approaches and therefore could eventually evolve into a novel therapeutic regimen for gastroesophageal cancer.